Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

J&J’s Stelara Shows Promise Against Lupus in Study

Bill Berkrot  |  November 7, 2017

(Reuters)—Johnson & Johnson’s blockbuster psoriasis drug ustekinumab (Stelara) led to a significant reduction in disease activity in patients with systemic lupus compared with a placebo in a midstage clinical trial, according to data released on Nov. 4. Ustekinumab is already approved for psoriasis, psoriatic arthritis and Crohn’s disease and had third-quarter sales of $1.12 billion….

Insurers Step Up Pitch for Obamacare as Government Slashes its Effort

Caroline Humer  |  November 7, 2017

NEW YORK (Reuters)—President Donald Trump’s 90% cut to Obamacare advertising has U.S. health insurers in many states digging deeper into their pockets to get the word out about 2018 enrollment, which opened last week. Independence Blue Cross, a health insurer in Pennsylvania, has commissioned a tractor-trailer truck to bring insurance consultants out to shopping centers…

Systemic Sclerosis Mortality Rate May Be Underestimated

Kurt Ullman  |  November 6, 2017

Systemic sclerosis (SSc) is a disease characterized by immunologic abnormalities, microvascular involvement and tissue fibrosis. In previous studies, 10-year survival rates ranged from 50–84%. However, there are concerns that these studies, using prevalent cohorts, are underestimating mortality. “While the prognosis of many rheumatic diseases has improved with the availability of more effective and targeted therapies,…

Researchers Examine Lifetime Risk of Total Hip Replacements

Arthritis Care & Research  |  November 6, 2017

Total hip replacement (THR) surgery is an effective way to reduce pain and improve function in people with advanced hip osteoarthritis (OA). In light of aging populations, there’s a need to use contemporary, population-level data to plan for future service provision. In a study designed to compare THR data across countries, researchers demonstrated a significant increase in the overall use of and lifetime risk for THR from 2003 to 2013. Women consistently had a higher lifetime risk of surgery than men in all five countries studied, whereas men in all five countries demonstrated a significant increase in lifetime risk for THR over time…

crystal light / shutterstock.com

Rheumatology Case Report: Hand Abnormalities Feature of Fetal Hydantoin Syndrome

Reshma Khan, MD, & Andrew Evans, DO  |  November 6, 2017

Research has shown that anticonvulsants are teratogens and pose a risk for fetal malformations. Meadow was the first to note a possible link between congenital abnormalities and maternal use of anticonvulsive drug in 1968.1 In 1974, Barr et al noted hypoplasia and irregular ossification of the digital distal phalanges with nail dystrophy in children born to…

Can Osteoarthritis Be Reversed?

Elizabeth Hofheinz, MPH, MEd  |  November 6, 2017

You may say the 30 million Americans with osteoarthritis (OA) are walking around with a Band-aid—or so it seems.1 That’s because there’s no actual cure for this disabling condition. However, an inter­national group of scientists is making headway on a method of eliminating aging—senescent—cells as a way to prevent or even reverse OA. Cartilage Disappears,…

Infiltrating the Disc: Mast Cells & Back Pain

Lara C. Pullen, PhD  |  November 6, 2017

Mast cells may become a therapeutic target for low back pain, according to new research. Researchers found mast cells can infiltrate intervertebral disc cells and play a role in their degeneration. Specifically, mast cells and the cytokine, IL-6, were both more likely to be found in painful intervertebral discs surgically removed from patients than in control discs…

Rheumatology Future Physician–Scientist Award Available for MD/PhD Students

From the College  |  November 5, 2017

The Rheumatology Research Foundation is now offering the Rheumatology Future Physician-Scientist Award to enhance the training of promising MD/PhD or DO/PhD students who intend to become physician-scientists. As part of the Foundation’s work to recruit and train the next generation of rheumatology professionals, the award supports the nation’s top emerging physician-scientists. S. Louis Bridges Jr., MD,…

Year in Review: The ACR Advances Education, Rheumatic Disease Awareness, Strategic Planning in 2017

Sharad Lakhanpal, MBBS, MD  |  November 5, 2017

It seems like yesterday I was asked to write my first presidential column, and here I am penning my last. It’s incredible how fast the time goes and yet how much gets done. That progress is made possible by the dedicated and talented group of ACR volunteers and staff. This year, the College has had…

Unwise Choices: EHRs, PBMs, Drug Costs Are Leading to Physician Burnout

Simon M. Helfgott, MD  |  November 5, 2017

My dear electronic health records How do I dislike thee? Let me count the ways Adaptation of Sonnet 43 By Elizabeth Barrett Browning, 1806–1861 As my tenure as physician editor winds down, it’s worth reviewing some of the more nettlesome issues confronting clinicians that have been previously discussed in these pages and gauge their current…

  • « Previous Page
  • 1
  • …
  • 382
  • 383
  • 384
  • 385
  • 386
  • …
  • 815
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences